Transcript Document
CANCER AUTOVACCINE (CAV) New specific active anticancer agent
From Science To Business
11-12 October 2006,
Kyiv
G.P.Potebnya
Telephone : 259-91-94; 259-08-75 E-mail : [email protected]
R.E.Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine Kyiv 03022, Ukraine 1
Proprietary information statement
The technology material presented in this talk is available for licensing or joint product development.
None of the slides contain any confidential or proprietary information.
2
Problem Description & Market Need
Cancer Diseases (on 100 000 populations):
In the world: 210
Central and East Europe:
Ukraine: 341
(
349
162000 in year 2005)
Russia: 314 CAV could be used for treatment 125000 of all cases of cancers in Ukraine.
3
Brief technology description
prof. D.G.Zatula
CAV prepared from autologous tumor cells and products of synthesis of a saprophytic microorganism B.subtilis B 7025; CAV introduced by hypodermic injections. The complete course consists of 3 injections with 7 day's interval. The revaccination will be carried out through 1 and 6 months; CAV prevented relapses and metastasis after surgery treatment, increased overall and relapse-free survival of patients; CAV is recommended as independent immunotherapeutic agent in the postoperative period.
4
1.
2.
3.
4.
5.
• 6.
Advantages
Wide specter cancer’s forms, where CAV treatment could be used.
CAV produced from own cells of patients, so there is no any risk of SPID, or other’s infection diseases and it’s need no control methods concerning alien infection agents.
CAV is most effective at the late stages of cancer. Effectiveness of CAV treatment may be compared, or better, then chemo- or radiotherapy, but without so characteristic for them toxic effects.
Cost of production and treatment by CAV more lower then chemo- or radiotherapy. Combination to other methods of therapy:
After radical operation (early stages of disease, the absence of metastasis) an effective utilization CAV without chemo- or radiotherapy. If it is necessary carryings out courses of chemo or the radiotherapies immunotherapy by CAV may be started in 18-21 days after their end.
5
EFFICACY ANTICANCER AUTOVACCINE DURING COMPLEX THERAPY IN STOMACH CANCER PATIENTS ( Overall survival)
20 10 0 60 50
Stomach cancer, stage ІІІ
Operation+ Vaccine Operation 40 30 5 10
years
• CAV treatment enhanced 5-years survival (57% versus 31%), 10-years survival (50% versus 27%); • CAV treatment of stomach cancer patients has no analogous.
6
EFFICACY ANTICANCER AUTOVACCINE DURING COMPLEX THERAPY IN LUNG CANCER PATIENTS ( Overall survival)
60 50 40 30 20 10 0
Lung cancer, stage ІІІА
Operation +Vaccine Operation 3 5
years
• CAV treatment enhanced 5-years survival (39% versus 10%); • CAV treatment of lung cancer patients has no analogous 7
Stage of development (clinical tests if medical) and international patents
CAV treatment were supported by National Academy of Science of Ukraine, Ministry of Health and Farmcommittee of Ukraine It was obtained permission (certificate) for using CAV in Ukraine’s clinics Now 8 clinics in country successfully use this treatment 8
Targeted Market Segment
•
CAV could be used for treatment of most spread cancers forms
Among them:
For men :
Lung cancer Stomach cancer Rectum cancer Colon cancer 21% 10% 6% 5%
For women:
Breast cancer - 21% Cervical cancer - 6% Rectum cancer- 5% Colon cancer - 6% 9
In comparison with existing products or methods Summary of 5-year' s survivals patients with rectum cancer (III stage), who were undertaken different forms of treatments
Treated patients Surgery Overall survival 29,0% Relapse-free survival 19,6% Surgery+ radiotherapy Surgery +Chemotherapy Surgery +Chemotherapy+CAV Surgery +CAV 42,7% 50,0% 77,0% 63,0% 34,0% 30,0% 30,0% 38,0% 10
Competitive Matrix
In comparison with another autologous anticancer vaccines (colon cancer –5 years survival)
Characteristics Overall survival Cost
R.E.Kavetsky Institute National Academy of Sciense, Kiev, Ukraine
78%
Massachusetts General Hospital, Boston, USA
83%
Department of Oncology, University Hospital, Antwerp, Belgium.
78% 100 $ 5000-30000 $ 5000-30000 $ Side effects 10-20% Components of vaccine
Tumor antigens +cytotoxic lectin B.subtilis
30-40% 70-90%
Living irradiated tumor cells+ living BCG Living irradiated tumor cells+ living BCG 11
Opportunities
1. In common work to obtain licences for CAV treatment in EC countries, USA and Russia 2. In common work to produce and use CAV in this countries
12
Contact information G.P.Potebnya
Telephone : 259-91-94; 259-08-75 E-mail : [email protected]
R.E.Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, National Academy of Science, Ukraine
13